Table 3. Principal studies on antiplatelet treatment in endovascular revascularization in LEAD and carotid artery disease.

Study name	District involved	Type of study	Design and study population	Primary endpoint	Main results
Aspirin
Cochrane review (24)	LEAD	Meta-analysis of various antiplatelet regimen	3,529 patients on various antiplatelet regimen (356 aspirin plus dipyridamole vs. placebo)	Reocclusion	OR 0.69 (95% CI, 0.44–1.10)
Clopidogrel
MIRROR (25)	LEAD	Randomized	80 patients, DAPT (aspirin plus clopidogrel) vs. aspirin monotherapy	Target lesion revascularization	5% vs. 20%; P=0.04
McKevitt (26)	Carotid stenosis	Randomized, double blind	DAPT (aspirin plus clopidogrel) vs. aspirin + heparin	Neurological complications and 30-day stenosis rates	Neurological complication 25% vs. 0%; P=0.02
					30-day stenosis 26% vs. 5%; P=0.1
ARMYDA CAROTID (27)	Carotid stenosis	Randomized, double blind, 2×2 factorial	156 patients, clopidogrel 600 mg load vs. 300 mg load	30-day TIA/stroke or new ischemic lesions on MRI 24 to 48 h	18% vs. 35.9%; P=0.019
Cilostazol
STOP-IC (28)	LEAD	Randomized, double blind	200 patients, cilostazol plus aspirin vs. aspirin monotherapy	Angiographic restenosis	20% vs. 49%; P=0.0001